|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Assessment of interobserver variation in Garden classification and management of fresh intracapsular femoral neck fracture in adults显示文摘ObjectiveTo 在如果侧面的看法的增加改变整形外科的外科医生被要求仅仅在 AP 看法上分类 35 大腿骨的颈破裂并且建议管理的分类和管理 plan.MethodsTen ,骨折和管理计划基于 anteroposterior ( AP )看并且也估计的新鲜的大腿骨的颈的花园分类上估计 interobserver 协议计划。当时,一样的电影是在 10 天以后与他们的侧面的看法一起重新显示出。结果与到在二个组之间的分类和管理计划的尊重相比。Interobserver 同意用 Fleiss’ 被计算kappa.ResultsThere 仅仅仅仅在 AP 看法上的花园分类上是一个公平 interobserver 协议(kappa 价值 0.39 ) 它改善了在增加一个侧面的看法以后节制同意(kappa 价值 0.52 ) 。当仅仅在 AP 上的管理计划上的 interobserver 协议有细微改进时,仅仅看(kappa 价值 0.50 ) 并且 AP 与侧面的看法(kappa 价值 0.52 ) 结合了。侧面的看法的补充在 15.42% 盒子中改变了分类并且在 23.14% cases.ConclusionWe 改变了管理计划断定当它毫无疑问在计划大腿骨的颈骨折的治疗有一个角色,那个侧面的看法应该与怀疑的大腿骨的颈骨折在所有病人上习惯性地被获得。 | Amit Aggarwal Mahipal Singh Aditya N Aggarwal Shuchi Bhatt | 2014 | Chinese Journal of Traumatology2014，17，2： | 13 |
| 2 | Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions显示文摘Colon cancer continues to be one of the leading causes of mortality and morbidity throughout the world despite the availability of reliable screening tools and effective therapies.The majority of patients with colon cancer are diagnosed at an early stage(stages I to III),which provides an opportunity for cure.The current treatment paradigm of early stage colon cancer consists of surgery followed by adjuvant chemotherapy in a select group of patients,which is directed at the eradication of minimal residual disease to achieve a cure.Surgery alone is curative for the vast majority of colon cancer patients.Currently,surgery and adjuvant chemotherapy can achieve long term survival in about two-thirds of colon cancer patients with nodal involvement.Adjuvant chemotherapy is recommended for all patients with stage III colon cancer,while the benefit in stage II patients is not unequivocally established despite several large clinical trials.Contemporary research in early stage colon cancer is focused on minimally invasive surgical techniques,strategies to limit treatment-related toxicities,precise patient selection for adjuvant therapy,utilization of molecular and clinicopathologic information to personalize therapy and exploration of new therapies exploiting the evolving knowledge of tumor biology.In this review,we will discuss the current standard treatment,evolving treatment paradigms,and the emerging biomarkers,that will likely help improve patient selection and personalization of therapy leading to superior outcomes. | Sakti Chakrabarti Carrie Y Peterson Deepika Sriram Amit Mahipal | 2020 | World Journal of Gastrointestinal Oncology2020，12，8： | 4 |
| 3 | Management of borderline resectable pancreatic cancer显示文摘Pancreatic cancer is the fourth most common cause of cancer death in the United States. Surgery remains the only curative option; however only 20% of the patients have resectable disease at the time of initialpresentation. The definition of borderline resectable pancreatic cancer is not uniform but generally denotes to regional vessel involvement that makes it unlikely to have negative surgical margins. The accurate staging of pancreatic cancer requires triple phase computed tomography or magnetic resonance imaging of the pancreas. Management of patients with borderline resectable pancreatic cancer remains unclear. The data for treatment of these patients is primarily derived from retrospective single institution experience. The prospective trials have been plagued by small numbers and poor accrual. Neoadjuvant therapy is recommended and typically consists of chemotherapy and radiation therapy. The chemotherapeutic regimens continue to evolve along with type and dose of radiation therapy. Gemcitabine or 5-fluorouracil based chemotherapeutic combinations are administered. The type and dose of radiation vary among different institutions. With neoadjuvant treatment, approximately 50% of the patients are able to undergo surgical resections with negative margins obtained in greater than 80% of the patients. Newer trials are attempting to standardize the definition of borderline resectable pancreatic cancer and treatment regimens. In this review, we outline the definition, imaging requirements and management of patients with borderline resectable pancreatic cancer. | Amit Mahipal Jessica Frakes Sarah Hoffe Richard Kim | 2015 | World Journal of Gastrointestinal Oncology2015，7，10： | 3 |
| 4 | Comment on:development and external validation of a model to predict overall survival in patients with resected gallbladder cancer显示文摘We read the study reported by Lohman et al.with interest published recently in the Annals of Surgery(1).The authors have developed a statistical model to predict the overall survival(OS)of patients with resected gall bladder cancer(GBC).Dutch national database was used to create and internally validate the model based on individual-level data(n=380).Subsequently,data from a cohort of Australian patients with resected GBC were used for external validation(n=66).The model was constructed based on the patient and tumor characteristics found to be independent predictors of OS that included age,tumor and node(T/N)classification,resection margin,tumor differentiation grade,and vascular invasion.The concordance index(C-index)in the internal and the external validation cohorts were 0.71[95%confidence interval(CI):0.69-0.72]and 0.75(95%CI:0.69-0.80),respectively,suggesting good discriminatory capacity.The authors also demonstrated that their model outperformed the discriminative capability of the American Joint Committee on Cancer(AJCC)staging system(8th edition)with a C-index of 0.59(95%CI:0.57-0.60).Furthermore,the authors constructed a web application that can predict the OS of a given patient based on a small number of clinicopathologic variables(age,T stage,N stage,resection margin,differentiation grade,and perivascular invasion). | Sakti Chakrabarti Amit Mahipal | 2022 | Hepatobiliary Surgery and Nutrition2022，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员